Primary care management of patients with liver disease

Includes discussion of TA337 on rifaximin-α for hepatic encephalopathy

Click here for prescribing information

Click here to view the on-demand webinar

Webinar primary care management of patients with liver disease

This webinar was commissioned and funded by Norgine Pharmaceuticals Limited and organised in partnership with Guidelines in Practice.  Norgine Pharmaceuticals Limited reviewed the scope of the webinar, worked with MGP Ltd to choose and commission speakers, and approved all materials related to the webinar. Norgine Pharmaceuticals Limited has paid the speaker honoraria. The views and opinions of the speakers are not necessarily those of Norgine Pharmaceuticals Limited, or of Guidelines in Practice, its publishers, advisers, or advertisers.

UK/XIF5/1017/0353
Date of Preparation: March 2018

Click here for prescribing information for Targaxan (rifaximin-α)  

Best practice in liver care